Natural Killer (NK) Cells With HLA Compatible Hematopoietic Transplantation for High Risk Myeloid Malignancies
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Natural killer cell therapy (Primary) ; Antithymocyte globulin; Busulfan; Filgrastim; Fludarabine; Interleukin-2; Methotrexate; Tacrolimus
- Indications Acute myeloid leukaemia; Chronic myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions; Therapeutic Use
- 04 Dec 2020 Biomarkers information updated
- 13 Jun 2013 New source identified and integrated (M.D. Anderson Cancer Center; 2012-0819).
- 12 Jun 2013 Planned end date changed from 1 Aug 2018 to 1 Jun 2018 as reported by ClinicalTrials.gov.